GNLX · GENELUX Corp
$2.87
+0.05 (+1.77%)
At close · Jul 17
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$128.69M
Shares
44.84M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.87
Open$2.80
Day$2.80–2.88
52W$2.29–8.54
Avg vol 30d178K
Short int3.0M · 6.7% float · 12.8d
Short vol54%
DataJan 2023–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−3%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
9%
near low
Momentum
relative strength
1-month return
+1%
trailing
6-month return
0%
trailing
YTD return
−34%
this year
Relative strength
−8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
7 of 72 funds reported for Jun 30 · net +18.1K sh shares
Insider flow
Distributing
Net -$77.9K over 90 days · 100% sells
Short interest
Falling
6.71% of float · ▼ -5.6% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
72 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+9%
Y/Y
Free cash flow
$-26.4M
Balance sheet
$5.3M
net cash
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−3%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
7 of 72 funds reported for Jun 30 · net +18.1K sh shares
Insider flow
Distributing
Net -$77.9K over 90 days · 100% sells
Short interest
Falling
6.71% of float · ▼ -5.6% MoM · 12.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
72 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $3 · 9%
52-wk high $9
vs 200-day avg -21%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GNLX
this stock
GENELUX Corp
|
$128.69M | -34.2% | +0.0% | — | 6.7% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GNLX | -5.3% | +0.7% | +0.0% | -4.7% | -34.2% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -3.7% | +0.4% | -7.8% | -4.2% | -43.2% |